The constant failure of new neuroprotective therapies for ischemic stroke has partially halted
the search for new therapies in recent years, mainly because of the high investment risk …

Neuroinflammation has emerged as a major concern in ischemic stroke therapy because it
exacebates neurological dysfunction and suppresses neurological recovery after …

In vitro and preclinical in vivo research in the last 35 years has clearly highlighted the crucial
physiopathological role of glial cells, namely astrocytes/microglia/oligodendrocytes and …

Background Ferroptosis plays a crucial role in the occurrence and development of cerebral
ischemia-reperfusion (I/R) injury and is regulated by mitogen-activated protein kinase 1/2 …

Introduction Cerebral edema is a key contributor to death and disability in several forms of
brain injury. Current treatment options are limited, reactive, and associated with significant …

Background and Purpose: Blood-brain barrier (BBB) disruption following ischemic stroke
(IS) contributes to hemorrhagic transformation, brain edema, increased neural dysfunction …

Sphingosine-1-phosphate (S1P) is a sphingolipid metabolic product produced via the
phosphorylation of sphingosine by sphingosine kinases (SPHKs), serving as a powerful …

Bone marrow mesenchymal stem cells (BMSCs) have therapeutic potential in the
subacute/chronic phase of acute ischemic stroke (AIS), but the underlying mechanisms are …

Osteoclast (OC) abnormalities lead to many osteolytic diseases, such as osteoporosis,
inflammatory bone erosion, and tumor‐induced osteolysis. Exploring effective strategies to …

Fingolimod has generally shown neuroprotective effects in stroke models. Here, we tested
the hypothesis that fingolimod modulates T‐cell cytokine production towards a regulatory …